

HER2/neu Antibody

Datasheet

For Research Use Only

Description	Catalog No.	Size
HER2/neu Concentrate	FP-A020-01	0.1 ml
HER2/neu Concentrate	FP-A020-10	1 ml
HER2/neu Predilute	FP-A020-70	7 ml
HER2/neu Predilute	FP-A020-250	25 ml

Description

The Her2/Neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between Her2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.

Specifications

Clone	IHC042
Source	Mouse Monoclonal
Applications	IHC (P)
Formulation	Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide

IHC Procedure*

Positive Control Tissue	Breast Carcinoma
Dilution Range	1:50 – 1:200
Pretreatment	Perform heat-induced epitope retrieval (HIER) at pH for 10 to 30 minutes
Incubation Time and Temp	10 to 30 minutes at room temperature
Detection	Refer to the corresponding user manual for detection system

Result




Figure. Her2/Neu on Breast

Storage and Handling

Must store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. To ensure proper stability and delivery of the antibody after each run, replace the cap and immediately place the bottle in a refrigerator in an upright position. Positive and negative controls should be simultaneously run with unknown specimens, as there are no conclusive characteristics to suggest instability of the antibody.

Precautions

The product is for research use only. Do not use for diagnosis purpose. Ensure proper handling procedures are used with all reagents. Always wear laboratory coats, disposable gloves, and other appropriate laboratory equipment when handling reagents. Do not ingest reagents, and avoid contact with eyes and mucous membranes. Wash eyes with copious amounts of water if contact occurs.

References

1. **Suthipintawong C**, et al. “Immunostaining of estrogen receptor, progesterone receptor, MIB1 antigen, and c-erbB-2 oncoprotein in cytologic specimens: a simplified method with formalin fixation.” *Diagn Cytopathol.* 1997; 17:127-33.
2. **Alexiev BA**, et al. “Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index.” *Gen Diagn Pathol.* 1997; 142:271-9.
3. **Fernández Aceñero MJ**, et al. “Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis.” *Gen Diagn Pathol.* 1997; 142:289-96.
4. **Koeppen HKW**, et al. “Overexpression of HER2/neu in solid tumours: an immunohistochemical survey.” *Histopathology.* 2001; 38:96-104.
5. **Moch H**, et al. “p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer.” *Virchows Arch A Pathol Anat Histopathol.* 1993; 423:329-34.
6. **Cetin B**, et al. “HER2/neu as target in gastric adenocarcinoma.” *Transl Gastroenterol Hepatol.* 2016; 1:59.

Technical Support

Contact FemtoPath Technical Support at +886232338585 or email to femtopath@hongjing.com.tw for assistance with more questions regarding this product.